EXACT Sciences Corp (EXAS)

HEALTH CARE: PHARMACEUTICALS
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

441 CHARMANY DRIVE MADISON, WI 53719

Applies its proprietary DNA-based technologies to the early detection of cancer. The company's first major commercial application is PreGen-Plus, a non-invasive DNA-based test for the early detection of colorectal cancer.

Data as of 2020-07-04
Market Cap12.992 Billion Shares Outstanding149.923 Million Avg 30-day Volume1.418 Million
P/E Ratio Dividend Yield EPS-0.7
Price/Sales15.069 Price cash flow ratio Price free cash flow ratio-10.2
Book Value16.93 Price to Tangible Book75.44 Alpha0.03
Short Interest Ratio % Short Interest to Float R-squared0.149159
BETA1.91366 52-week High/Low123.99 / 35.2512 Stddev0.211006
View SEC Filings from EXAS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 8 1 (0.07%)
13F Filers holding this stock: 451 94 (6.16%)
Aggregate 13F shares on 03/31/2020: 129.702 Million 39.998 Million
Aggregate 13F shares on 12/31/2019: 130.117 Million 44.432 Million
Percent change: -0.32% -9.98%
Funds creating new positions: 67 21
Funds Adding to an existing position: 170 33
Funds closing out their position: 106 33
Funds reducing their position: 148 34
Heat Map Ranking for 03/31/2020 293
Heat Map Ranking for 12/31/2019 178
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EXAS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EXAS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CONROY KEVIN T

  • Director
7,602 2020-06-30 6

ZENNER PATRICK J

66,140 2020-06-30 0

WYZGA MICHAEL S

  • Director
0 2020-06-19 2

ELLIOTT JEFFREY THOMAS

  • Director
0 2020-06-18 5

ZANOTTI KATHERINE S

  • Director
17,093 2020-06-15 2

COLE G BRADLEY

  • Director
0 2020-06-04 6

FALLON JOHN A.

  • Director
37,362 2020-06-02 0

CRAWFORD SALLY

  • Director
29,498 2020-05-28 0

BAKEWELL JOHN K

  • Director
0 2020-05-26 0

WILLSEY LANCE

  • Director
0 2020-05-21 0

LEWIS-HALL FREDA C

  • Director
  • 10% Owner
0 2020-05-20 2

PAULSEN GISELA GEN MGR, PRECISION ONCOLOGY

  • Officer
0 2020-04-20 2

STENHOUSE MARK PRESIDENT, COLOGUARD

  • Officer
29,926 2020-04-02 3

DOYLE JAMES EDWARD

  • Director
32,440 2020-02-28 3

SEBELIUS KATHLEEN

0 2020-02-20 1

ORVILLE JACOB A GENERAL MANAGER, NEW VENTURES

  • Officer
2,687 2020-02-18 3

HOOF TORSTEN GENERAL MANAGER, INTERNATIONAL

  • Officer
5,914 2020-02-15 3

KANIA EDWIN M JR

  • 10% Owner
23,847 2020-01-10 0

CASDIN ELI

  • Director
6,487 2019-11-08 2

JOHNSON SCOTT C. SVP - RESEARCH AND DEVELOPMENT

  • Officer
12,504 2019-09-11 1

LEVANGIE DANIEL J

  • Director
12,458 2019-07-31 2

CAREY THOMAS D.

  • Director
34,181 2019-07-31 2

SLAVITT ANDREW M

  • Director
5,387 2019-07-25 2

JACQUET PIERRE

  • Director
0 2019-07-25 2

HOOKER ANA SVP, OPERATIONS

  • Officer
76,474 2019-04-24 0

COWARD D SCOTT CHIEF ADMINISTRATIVE OFFICER

  • Officer
106,978 2019-03-09 0

THOMPSON DAVID

  • Director
166,671 2018-12-31 0

LIDGARD GRAHAM PETER CHIEF SCIENCE OFFICER

  • Officer
41,040 2018-11-05 0

ARORA MANEESH COO

  • Officer
  • Director
658,613 2018-03-09 0

STERLING LIONEL

  • Director
127,575 2017-07-27 0

LUBER JEFFREY R

  • Director
0 2016-02-04 0

MEGAN WILLIAM J. SVP, FINANCE

  • Officer
52,369 2015-08-26 0

MCGILLICUDY CORNELIUS III

  • Director
25,579 2014-01-08 0

CONNELLY JAMES P

  • Director
80,513 2013-08-27 0

STOLTENBERG LAURA S CHIEF COMMERCIAL OFFICER

  • Officer
27,273 2013-03-19 0

KRAYACICH JOHN M SVP, SALES AND MARKETING

  • Officer
4,500 2011-03-15 0

BERGER BARRY M SVP, CHIEF MEDICAL OFFICER

  • Officer
60,552 2010-01-07 0

CARELLI CHARLES R JR SVR, CFO, TREASURER & SECRETAR

  • Officer
0 2009-03-31 0

SINGER MICHAEL E

  • Director
540,193 2008-12-12 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments